Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial.
about
Low dose naltrexone for induction of remission in Crohn's diseaseAdipokines and the role of visceral adipose tissue in inflammatory bowel diseaseFacing Terminal Ileitis: Going Beyond Crohn's DiseaseThe use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic painObesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes.Measuring disease activity in Crohn's disease: what is currently available to the clinician.Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis.Low-dose naltrexone and opioid consumption: a drug utilization cohort study based on data from the Norwegian prescription database.Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot studyLow-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels.Randomized controlled trial: moxibustion and acupuncture for the treatment of Crohn's disease.A sudden and unprecedented increase in low dose naltrexone (LDN) prescribing in Norway. Patient and prescriber characteristics, and dispense patterns. A drug utilization cohort study.A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design.Crohn's and colitis in children and adolescents.Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives.Mucosal healing in Crohn's disease: a systematic review.Opioid antagonists for pain.Histologic scoring indices for evaluation of disease activity in Crohn's disease.Recent progress in the development of Toll-like receptor (TLR) antagonists.Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model.Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin.Naltrexone Inhibits IL-6 and TNFα Production in Human Immune Cell Subsets following Stimulation with Ligands for Intracellular Toll-Like Receptors.Gut Homeostasis, Microbial Dysbiosis, and Opioids.Targeted overexpression of OGFr in epithelium of transgenic mice suppresses cell proliferation and impairs full-thickness wound closure.Targeting opioid signaling in Crohn's disease: new therapeutic pathways.Do opioid receptors play a role in the pathogenesis of the inflammatory response in acute pancreatitis?Multi-modal MRI classifiers identify excessive alcohol consumption and treatment effects in the brain.The effect of Low Dose Naltrexone on Medication in Inflammatory Bowel Disease: A Quasi Experimental before-and-after Prescription Database Study.Low dose Naltrexone for induction of remission in inflammatory bowel disease patients.
P2860
Q24200319-F2A96B73-AC8B-4121-B6A5-CB958F03D9EAQ28070229-5583E003-4FD9-4C88-B081-ED827F6FD024Q28077774-5D55779B-6A3F-4331-A0D7-A42448AFF02AQ28307673-7FD990C2-07CF-4FE8-AB40-0C11CC755E1FQ30239737-D7D3FF43-29A5-40CD-B786-5CB2773BAE58Q33668961-1EE52508-117B-42F8-A7CD-306DE3AB6912Q33692797-7322D38C-0DBE-499B-A5A4-D98C804E5FDFQ33835804-B3D294E7-D4B2-4D70-B43D-70C5945D6A07Q34034566-E7005D2E-107F-42EF-96AF-1CB4B9A5B8A5Q34035333-D8B5AFBD-B653-40D9-8653-69015AE5F96BQ34067969-0BE923FD-7F6C-4F0F-8D79-723BFCC6CAFAQ34541162-6D96FA26-06DE-466F-907C-185ED65E7F89Q35207745-607392AE-6A20-4F63-8C88-ADBFD9547F20Q36378775-9ECE9D1A-DB13-4BA4-BF0D-382B134318E4Q37491434-DF4DBB25-3539-4643-AFC5-F1C4EAA6A5D9Q38005972-57D0EDC9-659C-4034-AE41-DF782416BBDBQ38088778-ECB8AD43-D558-40D5-BAC3-3C40536D0602Q38668188-9E5EF5A3-0751-42DB-B04F-A93D4A99B8A6Q38823065-6E25F8DD-E58E-4850-A0EA-B612548B0F25Q39496812-4E395870-5204-46B7-838D-2842CB35A685Q39522079-84976058-7D88-4492-B076-0DFE7B24FD99Q40119691-7CD841D6-611D-4BB2-8824-FFB4926E21ADQ40432327-7A9C4DDF-AEC9-45CB-94A9-5E1A90468CCDQ44031670-C077A610-17A4-4681-B5F0-55D09D97D10CQ44330585-627A2E79-5899-4C1B-822E-BCA67FF1EDCDQ44335777-E8DFC341-0214-4F8E-9381-75F26BB4EDD3Q45951025-6654040C-FFCD-4416-87CB-DE866047B1D7Q49552898-BD3DAB86-BAB7-4422-AC00-EEF9D8580A10Q52664057-1548139B-34D1-4167-B636-B15571E30078
P2860
Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Therapy with the opioid antago ...... ized placebo-controlled trial.
@ast
Therapy with the opioid antago ...... ized placebo-controlled trial.
@en
type
label
Therapy with the opioid antago ...... ized placebo-controlled trial.
@ast
Therapy with the opioid antago ...... ized placebo-controlled trial.
@en
prefLabel
Therapy with the opioid antago ...... ized placebo-controlled trial.
@ast
Therapy with the opioid antago ...... ized placebo-controlled trial.
@en
P2093
P2860
P921
P1476
Therapy with the opioid antago ...... ized placebo-controlled trial.
@en
P2093
Aparna Mukherjee
Christopher O McGovern
David T Mauger
Francesca Ruggiero
Ian S Zagon
Jill P Smith
Sandra I Bingaman
P2860
P2888
P304
P356
10.1007/S10620-011-1653-7
P577
2011-03-08T00:00:00Z